TN2013000213A1 - Solid dosage forms of oleyl phosphocholine - Google Patents
Solid dosage forms of oleyl phosphocholineInfo
- Publication number
- TN2013000213A1 TN2013000213A1 TNP2013000213A TN2013000213A TN2013000213A1 TN 2013000213 A1 TN2013000213 A1 TN 2013000213A1 TN P2013000213 A TNP2013000213 A TN P2013000213A TN 2013000213 A TN2013000213 A TN 2013000213A TN 2013000213 A1 TN2013000213 A1 TN 2013000213A1
- Authority
- TN
- Tunisia
- Prior art keywords
- solid dosage
- dosage form
- weight
- dosage forms
- present
- Prior art date
Links
- 239000007909 solid dosage form Substances 0.000 title abstract 10
- SLVOKEOPLJCHCQ-SEYXRHQNSA-N [(z)-octadec-9-enyl] 2-(trimethylazaniumyl)ethyl phosphate Chemical compound CCCCCCCC\C=C/CCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C SLVOKEOPLJCHCQ-SEYXRHQNSA-N 0.000 title abstract 3
- 239000003814 drug Substances 0.000 abstract 2
- 229920002785 Croscarmellose sodium Polymers 0.000 abstract 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 abstract 1
- 208000004554 Leishmaniasis Diseases 0.000 abstract 1
- 241001465754 Metazoa Species 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 208000030852 Parasitic disease Diseases 0.000 abstract 1
- VJHCJDRQFCCTHL-UHFFFAOYSA-N acetic acid 2,3,4,5,6-pentahydroxyhexanal Chemical compound CC(O)=O.OCC(O)C(O)C(O)C(O)C=O VJHCJDRQFCCTHL-UHFFFAOYSA-N 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000001913 cellulose Substances 0.000 abstract 1
- 229920002678 cellulose Polymers 0.000 abstract 1
- 229960005168 croscarmellose Drugs 0.000 abstract 1
- 239000001767 crosslinked sodium carboxy methyl cellulose Substances 0.000 abstract 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 abstract 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 abstract 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 abstract 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 abstract 1
- 239000008101 lactose Substances 0.000 abstract 1
- 239000000314 lubricant Substances 0.000 abstract 1
- 201000004792 malaria Diseases 0.000 abstract 1
- 238000000034 method Methods 0.000 abstract 1
Classifications
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to solid dosage forms of oleyl phosphocholine (C18:1-PC), or OlPC, for oral administration. Further, the present invention relates to methods for the preparation of the present solid dosage forms and the use thereof as a medicament and especially a medicament for treatment of parasitic diseases,such as leishmaniasis, chagas and malaria, and cancer both in humans and animals.Specifically, the present invention relates to a solid dosage form comprising:6 to 25 weight % of the solid dosage form oleylphosphocholine;20 to 35 weight% of the solid dosage form lactose;35 to 50 weight % of the solid dosage form cellulose;5 to 20 weight% of the solid dosage form croscarmellose;1 to 10 weight% of the solid dosage form hydroxypropylmethyl cellulose; and0.05 to 1 weight% of the solid dosage form of a lubricant.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| PCT/EP2011/070592 WO2012069427A1 (en) | 2010-11-22 | 2011-11-21 | Solid dosage forms of oleyl phosphocholine |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| TN2013000213A1 true TN2013000213A1 (en) | 2014-11-10 |
Family
ID=54360713
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| TNP2013000213A TN2013000213A1 (en) | 2011-11-21 | 2013-05-15 | Solid dosage forms of oleyl phosphocholine |
Country Status (1)
| Country | Link |
|---|---|
| TN (1) | TN2013000213A1 (en) |
-
2013
- 2013-05-15 TN TNP2013000213A patent/TN2013000213A1/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PH12015502691A1 (en) | Use of high dose pridopidine for treating huntington's disease | |
| CY1119490T1 (en) | PYRAZOLOPYROLIDINE PRODUCTS AND THEIR USE IN PATIENT TREATMENT | |
| TN2012000421A1 (en) | Pharmaceutical compositions of spiro-oxindole compound for topical administration and their use as therapeutic agents | |
| EA201590371A1 (en) | 1,4-DESIGNED PYRIDAZIN ANALOGUES AND METHODS OF TREATMENT RELATED TO SMN DEFICIENCY CONDITIONS | |
| MX2015016344A (en) | Imidazopyrrolidinone derivatives and their use in the treatment of disease. | |
| AR091006A1 (en) | PROLIPOSOMAL TESTOSTERONE FORMULATIONS | |
| PH12014502447A1 (en) | Use of high dose laquinimod for treating multiple sclerosis | |
| NZ702826A (en) | Oral formulations and lipophilic salts of methylnaltrexone | |
| MX339302B (en) | 6 - substituted 3 - (quinolin- 6 - ylthio) - [1,2,4] triazolo [4, 3 -a] pyradines as tyrosine kinase. | |
| PH12019500618A1 (en) | Pharmaceutical composition and method for treatment of non-alcoholic fatty liver disease | |
| GEP20156332B (en) | Pyrazoles as crth2 antagonists | |
| PH12013500371A1 (en) | Therapeutic agent for pain | |
| SG10201809506TA (en) | Pharmaceutical compositions comprising 7-(1h-imidazol-4-ylmethyl)-5,6,7,8-tetrahydro-quinoline for treating skin diseases and conditions | |
| BR112014016450A2 (en) | leukotriene b4 antagonist compound | |
| TN2013000213A1 (en) | Solid dosage forms of oleyl phosphocholine | |
| MX2014011843A (en) | Compounds for use in the treatment of neuroblastoma, ewing's sarcoma or rhabdomyosarcoma. | |
| BR112015028581A2 (en) | low dosage pharmaceutical composition, acid utilization, method for treatment of inflammatory disease and pharmaceutical composition | |
| EA201500366A1 (en) | APPLICATION OF 1-ADAMANTYLETYLOXY-3-MORFOLINO-2-PROPANOL OR ITS PHARMACEUTICALLY ADOPTABLE SALTS IN PHARMACEUTICAL COMPOSITIONS AS A NEURORTHINOPROTECTOR | |
| WO2012095500A3 (en) | Pharmaceutical compositions for the treatment of parasitic diseases, cancer, or skin diseases by topical administration | |
| PH12013501638A1 (en) | (5s,8s)-3-(4`-chlor-3`-fluor-4-methlybiphenyl-3-yl)-4-hydroxy-8-methoxy-1-azaspiro[4.5]dec-3-en-2-one (compound a) for treatment | |
| UA65561U (en) | method for prevention of delay of cow brood | |
| BR112014012817A2 (en) | pharmaceutical compositions comprising 7- (1h-imidazol-4-ylmethyl) -5,6,7,8-tetrahydro-quinoline for retinal neuroprotection | |
| MY166773A (en) | Deuterated 1-piperazino-3-phenyl indanes for treatment of schizophrenia | |
| UA79175U (en) | Method for etiotropic therapy of influenza and other acute respiratory viral diseases |